Core Viewpoint - Actinium Pharmaceuticals has entered into a research agreement with Memorial Sloan Kettering Cancer Center to enhance the understanding and application of Actimab-A, a targeted radiotherapy for acute myeloid leukemia (AML) [1][3] Group 1: Collaboration and Research Objectives - The collaboration aims to study Actimab-A in combination with targeted therapies such as FLT3 and menin inhibitors to define transcriptional profiles in AML cells [1] - The second objective is to evaluate the effectiveness of Actimab-A-based combinations on primary AML patient-derived samples, both from patients with and without prior treatment [1] Group 2: Actimab-A Profile and Clinical Results - Actimab-A has shown a mutation agnostic profile with positive clinical outcomes in high-risk relapsed and refractory AML patients, including those with TP53 mutations and prior treatments [2] - The drug has demonstrated mechanistic synergy with FLT3 inhibitors and menin inhibitors in preclinical studies, with FLT3 mutations present in approximately 25-30% of AML cases [2] Group 3: Company Strategy and Market Potential - The company aims to address the needs of over 100,000 patients with myeloid malignancies, representing a multi-billion-dollar market opportunity [3] - Actimab-A is being advanced into pivotal Phase 2/3 trials in combination with CLAG-M chemotherapy and other agents, indicating a strong commitment to improving patient outcomes [4][5] Group 4: Broader Development Plans - Actinium is also developing Actimab-A for solid tumor indications by targeting myeloid derived suppressor cells, which could enhance the efficacy of PD-1 checkpoint immunotherapies [3][5] - The company holds 230 patents related to the manufacture of the isotope Ac-225, indicating a robust intellectual property position [5]